Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics


Hoth Therapeutics, Inc. (HOTH): $1.59

-0.01 (-0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HOTH Stock Price Chart Interactive Chart >

Price chart for HOTH

HOTH Price/Volume Stats

Current price $1.59 52-week high $3.89
Prev. close $1.60 52-week low $1.27
Day low $1.56 Volume 343,200
Day high $1.60 Avg. volume 3,407,167
50-day MA $1.56 Dividend yield N/A
200-day MA $1.92 Market Cap 37.96M

Hoth Therapeutics, Inc. (HOTH) Company Bio


Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.


HOTH Latest News Stream


Event/Time News Detail
Loading, please wait...

HOTH Latest Social Stream


Loading social stream, please wait...

View Full HOTH Social Stream

Latest HOTH News From Around the Web

Below are the latest news stories about Hoth Therapeutics Inc that investors may wish to consider to help them evaluate HOTH as an investment opportunity.

Companies Like Hoth Therapeutics (NASDAQ:HOTH) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | June 10, 2021

Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of symptoms related to Alzheimer's disease.

Yahoo | June 7, 2021

Hoth Therapeutics Unveils Preclinical Results of HT-KIT Therapeutic Program

Hoth Therapeutics Inc (NASDAQ: HOTH) has reported results from a preclinical trial of HT-KIT, a new molecular entity under development to treat mast cell-derived cancers and anaphylaxis. HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival, and differentiation of bone marrow-derived hematopoietic stem cells. Key findings of the mouse models found that HT-KIT: Reduces KIT expression and ind

Yahoo | June 3, 2021

Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder presentation, reinforcing the potential of HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis.

Yahoo | June 3, 2021

Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis, on Thursday, June 3rd for interested shareholders. Dr. Glenn Cruse, Ph.D., Assistant Professor at North Carolina State University, who developed HT-KIT, will present the preclinical animal results that are part of the Company's ASCO Exhibition.

Yahoo | June 1, 2021

Read More 'HOTH' Stories Here

HOTH Price Returns

1-mo 21.37%
3-mo -26.05%
6-mo -7.02%
1-year -39.54%
3-year N/A
5-year N/A
YTD -32.91%
2020 -61.71%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7528 seconds.